인간 마이크로바이옴 시장 규모, 점유율, 성장 분석 : 제품별, 질병별, 유형별, 최종사용자별, 지역별 - 산업 예측(2024-2031년)

Global Human Microbiome Market size was valued at USD 0.8 Billion in 2022 and is poised to grow from USD 1.01 Billion in 2023 to USD 9.7 Billion by 2031, growing at a CAGR of 31.80% during the forecast period (2024-2031).

The human microbiome has emerged as a pivotal area of research, particularly due to its significant connections to respiratory and immune health. Studies have shown a correlation between gut microbiota composition-specifically populations of actinobacteria, firmicutes, and bacteroidetes-and respiratory issues, highlighting the critical role of microbiome health in overall immunity. For instance, advancements in microbiome therapies have been initiated to bolster immune response against emerging pathogens like SARS-CoV-2. Additionally, the pandemic has heightened awareness surrounding microbial diagnostics and chemistry, creating a robust market for microbiota research and applications. This trend is poised to continue in the post-pandemic landscape, fueled by an increasing prevalence of lifestyle-related diseases and an aging population, with projections estimating 69 million individuals aged 20-79 will have diabetes by 2045, according to the International Diabetes Association. Moreover, the human microbiome market is being propelled by the growing utilization of microbiota in diverse health applications, including dietary supplements and dermatological treatments. Technological innovations, particularly next-generation sequencing and advanced microbial characterization methods, are further facilitating growth within this sector. Overall, the intersection of health awareness, demographic shifts, and technological advancements underscores the potential for significant expansion in the human microbiome market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Microbiome Market Segmental Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal disorders, obesity, and diabetes, significantly propels the Global Human Microbiome market. As scientific research increasingly elucidates the relationship between gut microbiota and these health issues, there is a burgeoning demand for microbiome-based treatments and interventions. This trend is fueling interest among both healthcare professionals and patients, resulting in heightened investments in research and development, as well as the commercialization of microbiome-related products. Consequently, this market is experiencing robust growth, as stakeholders recognize the potential of microbiome-targeted therapies to address pressing health challenges and improve patient outcomes.

Restraints in the Global Human Microbiome Market

A significant restraint in the Global Human Microbiome market is the exorbitant costs associated with research and development. The intricate nature of studying microbial communities and effectively translating these insights into viable therapies necessitates substantial financial and technical resources. Furthermore, the lengthy process of clinical trials, coupled with stringent regulatory approvals, adds layers of expense and complexity, which can hinder innovation and timely market entry of new products. As companies grapple with these financial constraints, the pace of advancements within the human microbiome sector may be slowed, limiting the potential growth and evolution of therapies aimed at leveraging this complex ecosystem.

Market Trends of the Global Human Microbiome Market

The Global Human Microbiome Market is witnessing a significant trend towards personalized medicine, driven by advancements in understanding the intricate relationship between microbial composition and individual health. As researchers and pharmaceutical companies increasingly focus on tailoring therapeutic interventions to specific microbial profiles, this approach results in more precise treatments and diagnostics for microbiota-related conditions. Not only does this trend enhance the efficacy of therapeutic agents, but it also fosters the development of innovative strategies to address diverse health issues. Consequently, the market is poised for growth as personalized microbiome-based solutions become integral to modern healthcare practices.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Technology Analysis
• Patent Analysis
• Regulatory Landscape

Human Microbiome Market by Product

• Market Overview
• Drugs
• Probiotics
• Prebiotics
• Synbiotics

Human Microbiome Market by Disease

• Market Overview
• Infectious Diseases
• Gastrointestinal Diseases
• Endocrine & Metabolic Disorders
• Other Diseases

Human Microbiome Market by Type

• Market Overview
• Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
• Live Biotherapeutic Product
• Others

Human Microbiome Market by End User

• Market Overview
• Hospitals and Clinics
• Long-Term Care Facilities
• Other End Users

Human Microbiome Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Seres Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomebank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quantbiome, Inc. (Dba Ombre) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maat Pharma SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotx Health Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlogic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aobiome (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siolta Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alveolus Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MRM Health NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biome Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanzyme Biologics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomx (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nubiyota (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quorum Innovations (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments